Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulate inflammatory processes at high doses

Planta Medica

Volumn 69, Issue 1, 2003, Pages 44-49

  Johnson, Victor J ^a   He, Quanren ^a   Osuchowski, Marcin F ^a,b   Sharma, Raghubir P ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Asteraceae; Cytokine; Inflammation; Natural product; Silyburn marianum; Silymarin; T lymphocyte

Indexed keywords

ANTIOXIDANT; FLAVANOID; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; PHYTOHEMAGGLUTININ; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PROTEIN EXPRESSION; SPLEEN CELL;

ANIMALS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED BALB C; SILYMARIN; T-LYMPHOCYTES;

ANIMALIA; ASTERACEAE; CIRSIUM; SILYBUM MARIANUM;

EID: 0037280468     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37023     Document Type: Article

References (23)

1. Hahn G, Lehmann HD, Kurten M, Uebel H, Vogel G. On the pharmacology and toxicology of silymarin, and antihepatotoxic active principle from Silybum marianum. Arzneimittel-Forschung/Drug Research 1968; 18: 698-704
2. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SNECAR mouse skin tumorogenisis model. Cancer Research 1999; 59: 622-32
3. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NK-κB, c-Jun N-terminal kinase, and apoptosis. The Journal of Immunology 1999; 163: 6800-9
4. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology 1989; 9: 105-13
5. Greimel A, Koch H. Silymarin - An inhibitor of horseradish peroxidase. Experimentia 1977; 33: 1417-8
6. Lang I, Deak G, Muzes G, Pronai L, Feher J. Effect of natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro. Biotechnology therapeutics 1993; 4: 263-70
7. Lang I, Deak GY, Nekam K, Muzes GY, Gonzalez-Cabello R, Gergely P, Feher J. Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Medica Hungaria 1988; 45: 287-95
8. Agoston M, Cabello RG, Blazovics A, Feher J, Vereckei A. The effect of amiodarone and/or antioxidant treatment on splenocyte blast transformation. Clinica Chimica Acta 2001; 303: 87-94
9. Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D, Zanussi C. Silybin inhibition of human T-lymphocyte activation. International Journal of Tissue Reactions 1988; 10: 177-81
10. Tager M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radical Research 2001; 34: 137-51
11. Kang SN, Lee MH, Kim KM, Cho D, Kim TS. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochemical Pharmacology 2001; 61: 1487-95
12. Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFα. Biochemical and Biophysical Research Communications 1997; 239: 334-9
13. Cho JY, Kim PS, Park J, Yoo ES, Baik KU, Kim Y, Park MH. Inhibition of tumor necrosis factor-a production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa. Journal of Ethnopharmacology 2000; 70: 127-33
14. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-κB activation by the flavonoid hepatoprotector silymarin in HepG2: Evidence for different activating pathways. FEBS Letters 1998; 440: 8-12
15. Letteron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, Larrey D, Pessayre D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochemical Pharmacology 1990; 39: 2027-34
16. 1 and c-myc in liver with marginal effects on other genes. Planta Medica 2002; 68: 676-9
17. 1. International Immunopharmacology 2001; 1: 2023-34
18. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Medica 1989; 55: 420-2
19. Lang I, Deak G, Muzes G, Pronai L, Feher J. Effect of the natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro. Biotechnology Therapeutics 1993; 4: 263-70
20. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chemistry and Biology 1995; 2: 13-22
21. Li JJ, Oberley LW, Fan M, Colburn NH. Inhibition of AP-1 and NF-κB by manganese-containing superoxide dismutase in human breast cancer cells. FASEB Journal 1998; 12: 1713-23
22. 2 and nitric oxide in inducible nitric oxide synthase expression in macrophages. Nitric Oxide 2001; 5: 504-13
23. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M, Luketic V, Coppel RL, Ansari AA, Gershwin ME. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. Journal of Experimental Medicine 2002; 195: 113-23